EP0402116B1 - Proteins, vaccines and nucleic acids - Google Patents

Proteins, vaccines and nucleic acids Download PDF

Info

Publication number
EP0402116B1
EP0402116B1 EP90306154A EP90306154A EP0402116B1 EP 0402116 B1 EP0402116 B1 EP 0402116B1 EP 90306154 A EP90306154 A EP 90306154A EP 90306154 A EP90306154 A EP 90306154A EP 0402116 B1 EP0402116 B1 EP 0402116B1
Authority
EP
European Patent Office
Prior art keywords
virus
protein
dna
sequence
rna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP90306154A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP0402116A1 (en
Inventor
Franz X. Heinz
Christian W. Mandl
Christian Kunz
Friedrich Dorner
Walter Bodemer
Gerhard Antoine
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oesterreichisches Institut fuer Haemoderivate
Original Assignee
Immuno AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immuno AG filed Critical Immuno AG
Publication of EP0402116A1 publication Critical patent/EP0402116A1/en
Application granted granted Critical
Publication of EP0402116B1 publication Critical patent/EP0402116B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present invention relates to vaccines and diagnostic agents for western subtype TBE virus, and to nucleic acid and proteins useful for such vaccines and agents.
  • TBE virus Western subtype tick-borne encephalitis (TBE) virus is a member of the family flaviviridae, which are spherical lipid enveloped RNA viruses (Westaway et al, Intervirology 24 , 183-192, 1985). The prototype virus is yellow fever virus. By definition, all flaviviruses are serologically related as revealed by hemagglutination-inhibition assays. By cross-neutralisation, however, the family can be subgrouped into several serocomplexes (DeMadrid and Porterfield, J. Gen. Virol. 23, , 91-96, 1974) comprising more closely related flaviviruses as opposed to serologically more distantly related viruses of different serocomplexes or ungrouped flaviviruses. TBE virus is a member of the so-called tick-borne serocomplex, which in addition also contains viruses termed Louping ill, Langat, Omsk hemorrhagic fever, Kyasanur Forest disease, and Negishi
  • TBE virus strains could be further assigned to a Western (European) subtype which is primarily transmitted by Ixodes ricinus and a Far Eastern subtype with Ixodes persulcatus as its main vector (Clarke, 1964; Bull. WHO 31, 45-56).
  • Mature virus particles contain only 3 structural proteins, termed E, C, and M with approximate molecular weights of 50 to 60,000, 15000, and 7000, respectively.
  • flaviviruses consists of single-stranded RNA of about 11000 bases with mRNA polarity having a molecular weight of 4 x 10 6 daltons. Together with the C-protein, this RNA forms a spherical nucleocapsid which is surrounded by a lipid envelope associated with both the proteins E and M.
  • E represents the viral hemagglutinin, ie, it causes agglutination of certain erythrocytes under appropriate conditions, which upon immunisation, induces hemagglutination-inhibiting, neutralising and protective antibodies, as well as immunity against challenge with live virulent virus (Heinz et al, Infect. Immun. 33 , 250-257, 1981).
  • flaviviruses The genome organisation of flaviviruses has recently been determined by cDNA cloning and sequencing of yellow fever, West Nile and Murray Valley encephalitis virus (Rice et al, Science 229 , 726-733, 1985; Dalgarno et al, J. Mol. Biol. 187 , 309-323, 1986; Castle et al, Virology 147 , 227-236, 1985; Castle et al, Virology 149 , 10-26, 1986; Wengler et al, Virology 147 , 264-274, 1985). According to these analyses, the genome RNA of flaviviruses contains a single long open reading frame of about 11,000 nucleotides which codes for all structural and non-structural proteins.
  • the gene order established for YF virus and confirmed for several other flaviviruses is 5;C-prM(M)-E-NS1-NS2A-NS2B-NS3-NS4A-NS4B-NS5 3.
  • C, prM(M) and E represent structural proteins found in immature (c, prM, E) and mature (C, M, E) virus particles, whereas the rest of the genome codes for non-structural proteins.
  • the structural proteins and the non-structural proteins have been positively identified by amino-terminal sequence analysis and have thus been correlated with the corresponding genome segments.
  • flaviviruses About 60 different flaviviruses have been recognised up to now and about two-thirds of them are transmitted by the bite of infected arthropods, thus representing arthropod-borne (ARBO) viruses.
  • ARBO arthropod-borne
  • flaviviruses are well known human pathogens and include yellow fever virus, dengue virus, Japanese encephalitis virus, or tick-borne encephalitis virus (Shope, in: "The Togaviruses", pp. 47-82, Academic Press, New York, 1980).
  • TBE virus is endemic in many European countries, Russia and China. The disease is well documented in some Central European countries such as Austria, Czechoslovakia and Hungary, and several hundred hospitalised cases are recorded each year. This represents a significant public health problem.
  • the disease can be effectively prevented by vaccination with a highly purified formalin-inactivated whole virus vaccine (Kunz et al, J Med. Virol 6 , 103-109, 1980) which induces an immune response against the structural proteins of the virus.
  • a highly purified formalin-inactivated whole virus vaccine Keratin-inactivated whole virus vaccine (Kunz et al, J Med. Virol 6 , 103-109, 1980) which induces an immune response against the structural proteins of the virus.
  • the principal disadvantage of this vaccine is that large volumes of infectious and potentially hazardous virus suspensions have to be handled in the course of the manufacturing process. Thus extensive and expensive safety precautions are required.
  • EP-A-0284791 addressed the problem by providing a DNA molecule that comprises Western subtype TBE virus derived DNA, coding for at least a part of at least one structural protein, ie selected from the group comprising the proteins C, prM, M or E, of Western subtype TBE virus.
  • Such a DNA molecule corresponds to the single stranded RNA of Western subtype TBE virus, and proved suitable for providing genetic information for expressing a polypeptide which may be the entire protein C, prM, M or E of Western subtype TBE virus, as described above, or part of one of the above-mentioned proteins.
  • a polypeptide can be used diagnostically or therapeutically for example in the preparation of a vaccine.
  • sequence analysis also confirmed the differentiation from the Far Eastern subtype by revealing an amino acid sequence diversity of up to 14 (depending on the protein) as compared to the Far Eastern subtype (Yamshchikov and Pletnov, Nucleic Acid Res. 16 7750 (1988)).
  • EP-A-0284791 may well represent an improvement over an inactivated whole virus vaccine from the manufacturing point of view, it shares with the inactivated whole virus vaccine the disadvantage that it does not contain non-structural proteins, which may contribute to a protective immune response.
  • the non-structural proteins have important functions for the life cycle of flaviviruses being involved in virus maturation, proteolytic processing and RNA replication.
  • one of the non-structural proteins (NS 1) has been shown for certain flaviviruses other than TBE to be capable of inducing a protective immune response (Schlessinger et al , J. Gen. Virol 68 853-857 (1987); Zhang et al , J. Virol . 62 3027-3031 (1988)) in experimental animals, there has been no such disclosure for non-structural proteins of TBE.
  • NS-1 protein of the Western subtype of TBE virus has now been identified by its sequence. This protein is a useful vaccine component and may conveniently be produced by recombinant DNA technology.
  • a peptide or polypeptide comprising the amino acid sequence of the NS-1 protein of Western subtype TBE virus as shown in Figure 4.
  • peptides or polypeptides of this invention may therefore be provided in substantially pure form and/or substantially free of other substances with which they are naturally associated.
  • Peptides or polypeptides according to first aspect of this invention may be useful on their own or in conjuction with one or more appropriate excipients as diagnostic agents and as ingredients in the manufacture of vaccines.
  • the peptides or polypeptides are comprised in a composition which can be used in the medical field.
  • a vaccine composition comprising a peptide or polypeptide in accordance with the first aspect of the invention and one or more additional pharmaceutically acceptable components.
  • Such components may include a pharmaceutically acceptable carrier or adjuvant for the peptide or polypeptide.
  • Other suitable components may include a buffer.
  • the vaccine carrier may be any suitable carrier and may comprise one or more adjuvants if necessary. In accordance with usual practice all vaccine compositions in accordance with this invention may be sterile.
  • vaccines containing antigenic peptides or polypeptides is for preparing specific immunoglobulins, for example monoclonal or polyclonal antibodies, which may be prepared by methods known to those skilled in the art.
  • Antibodies against the peptides and polypeptides may also be regarded as forming part of the invention.
  • compositions comprising one or more of the peptides or polypeptides according to this invention may also be used as a diagnostic reagent.
  • the invention also relates to nucleic acid coding for peptides or polypeptides in accordance with the first aspect.
  • nucleic acid coding for the NS-1 protein of Western subtype TBE virus there is provided nucleic acid coding for the NS-1 protein of Western subtype TBE virus.
  • the nucleic acid which may and often will be recombinant nucleic acid, particularly recombinant DNA, can code for the whole, or substantially the whole of the NS-1 protein.
  • DNA and RNA molecules useful for providing the peptides or polypeptides in accordance with the first aspect, they may also be used in preparing a live vaccine.
  • the DNA sequences are combined with the DNA of Vaccinia virus which is well established as a live vaccine.
  • DNA or RNA sequences according to this invention are additionally suitable as probes for screening purposes.
  • DNA molecules there are a number of ways for preparing DNA molecules within the scope of this invention.
  • One possibility of obtaining the DNA molecule is first to extract the viral RNA from Western subtype TBE virus and purify the RNA molecule, followed by transcription of this RNA template into a DNA molecule using reverse transcriptase.
  • a further possibility is chemically to synthesise the DNA molecules according this invention, once the DNA sequence has been investigated.
  • this invention includes DNA molecules which hybridise to DNA molecules according to the first aspect, and particularly to a DNA sequence as shown in Figure 3 and/or a DNA sequence coding for a protein sequence as shown in Figure 4, under stringent conditions, eg selecting for at least 90% nucleotide sequence homology.
  • DNA molecules of this preferred kind may still code for peptides being able to cause antibody responses, and furthermore, those DNA molecules are suitable as DNA probes.
  • nucleic acid including the complete sequence of wild-type Western subtype TBE virus genome coding for the non-structural protein NS-1 is provided as well as DNA molecules derived from the genomic RNA coding for the protein.
  • DNA molecules within the scope of the invention may correspond to or be complementary with the single stranded RNA of Western subtype TBE virus, and are suitable for providing genetic information for expressing the whole NS-1 protein or one or more parts thereof which can usefully be used as a vaccine component or for diagnostic and therapeutic purposes.
  • the present invention includes explicitly all DNA sequences which differ from the DNA molecules corresponding or complementary to a natural NS-1 RNA sequence whether by degeneration of the genetic code and/or mutations and/or transpositions, which are in the normal range of natural variation of Western subtype TBE virus. These sequences therefore still code for proteins having the essential properties (particularly the essential antigenic properties) of the NS- 1 non-structural protein of Western subtype TBE virus.
  • the claimed DNA molecules can be combined with additional DNA sequences.
  • DNA sequences may allow replication and expression of the DNA molecule in a cell culture.
  • the most important DNA sequences for this purpose are those which function as promoters, enhancers, polyadenylation signals, and splicing signals.
  • These additional DNA sequences may be combined with the DNA molecules in accordance with the first aspect of the invention according to standard procedures known to those skilled in the art.
  • RNA molecules according to this invention may be obtained by isolation and purification of Western subtype TBE virus RNA, or by recombinant RNA/DNA techniques. Furthermore, not only are RNA molecules obtained by purification of the Western subtype TBE virus included in this invention, but also RNA molecules which have been obtained by transcribing isolated and purified virus RNA into DNA by reverse transcriptase and subsequent transcription of DNA thus obtained into RNA again, or by RNA-dependent RNA transcription.
  • a vector which may be a cloning vector or an expression vector, comprising a nucleic acid sequence in accordance with the third aspect.
  • the vector may for example be a plasmid, virus (for example an animal (eg vaccinia) virus or a phage) or cosmid.
  • virus for example an animal (eg vaccinia) virus or a phage
  • cosmid As is known in the art, such vectors generally comprise sequences which control replication and expression of the inserted RNA or DNA sequences; such control sequences may comprise a promoter and possibly additionally an enhancer, among other sequences.
  • a host cell containing a vector as described above. Many such cells may be provided in a cell culture.
  • the vectors are preferably contained in cell cultures in which the expression of the polypeptides coded for by the RNA or DNA sequences is according to this invention, the cell culture being preferably a mammalian cell culture.
  • the cell culture being preferably a mammalian cell culture.
  • the most preferred conditions are provided for expression of a polypeptide which is intended to be used as a vaccine for preventing mammals from Western subtype TBE virus infections.
  • FIGURE 1 shows a photograph of agarose gel electrophoresis of the undigested plasmid 85 17-6 (lane b), which contains the entire coding sequence for the NS1 protein.
  • Lane c shows a Bam HI digest of the same plasmid and the two lanes a contain 0.6Kb, 2Kb and 10Kb size markers.
  • FIGURE 2 shows the complete nucleotide sequence of insert 17-6, contained in plasmid BS 17-6.
  • FIGURE 3 shows the RNA sequence and the encoded amino acid sequence of insert 17-6.
  • the position numbers relate to the full length genome of TBE virus.
  • FIGURE 4 shows the amino acid sequence of protein NS1 as derived from the sequence information of clone 17-6. Position numbers are counted from the first amino acid of protein NS1.
  • FIGURE 5 shows a strategy for cloning NS1 into the prokaryotic expression vector pUC19S.
  • FIGURES 6A and 6B show nucleotide sequences of clone pNS1387 at the 5′ and3′ termini.
  • An NS1 insert is in frame with the bacterial lacZ gene. Expression is under the control of the lacZ operator/promoter system.
  • FIGURE 6A the general organisation of the construct is shown.
  • FIGURE 6B the DNA and protein sequences are indicated.
  • the NS1 has 40 additional nucleotides corresponding to 14 amino acids from the lacZ gene and the pUC19S polylinker at its 5′-end. There are an additional 27 non-NS1 nucleotides (corresponding to 9 amino acids) at the 3′-end. Nucleotide positions relative to the TBE genome, taken from FIGURE 3, are indicated by asterisks.
  • FIGURE 7A shows a strategy for cloning NS1 with its authentic 5′ signal sequence into the prokaryotic expression vector pUC19S.
  • FIGURE 7B shows nucleotide sequences of clone ptSNS1791 at the 5′ and 3′ termini.
  • the NS1 insert is in frame with the bacterial lacZ gene expression under the control of the lacZ promotor system.
  • the general organization of the construct is shown.
  • DNA and protein sequences are indicated.
  • the NS1 has 39 additional nucleotides corresponding to 13 amino acids from the lacZ gene and the pUC19S polylinker at its 5′-end.
  • FIGURE 8A shows the cloning of the NS1 coding region into the transfer vector pTKgptF1s for recombination with vaccinia virus.
  • FIGURE 8B shows the nucleotide sequences of clone pAPNS1338 at the 5′ and 3′ termini.
  • the NS1 has 19 additional nucleotides corresponding to 7 amino acids in its expected translation product from the polylinker region at its 5′-end additional 30 nucleotides, corresponding to 10 amino acids, are found at the 3′-end.
  • Asterisks indicate the nucleotide positions in the TBE Virus genome taken from FIGURE 3.
  • FIGURES 9A and 9B show the cloning of NS1 and its putative signal sequence by the polymerase chain reaction (PCR).
  • FIGURE 8A shows a generalised strategy for the PCR.
  • FIGURE 8B shows the sequence of chemically synthesised oligonucleotides used as primers for the DNA amplification.
  • the asterisks indicate the nucleotide positions in the viral genome according to FIGURE 3.
  • FIGURE 10 also referred to in Example 13, shows an agarose gel showing the NS1 fragment synthesised by PCR.
  • the agarose gel is stained with ethidium bromide. DNA is detected under u/v light.
  • the arrow indicates the fragment which is about 1130 bp long.
  • FIGURE 11 also referred to in Example 13, shows the cloning of the NS1 coding region with its putative signal sequence after synthesis by PCR into the transfer vector pSC11-OrthDELTA0 for recombination with vaccinia virus.
  • FIGURE 12 also referred to in Example 13, shows the sequences of clone pSCtSNS1444 at the 3′ and 5′ termini.
  • the authentic NS1 coding region including its signal sequence, acquires in its expected translation product 12 additional nucleotides, corresponding to four amino acids, from the polylinker region at its 5′-end.
  • An additional 47 nucleotides ie 16 amino acids are found at the 3′-end.
  • Asterisks indicate the nucleotide positions in the TBE virus genome, taken from FIGURE 3.
  • FIGURE 13 also referred to in Example 13, shows an analysis of the plasmid pSCtSNS1444 by digestion with appropriate restriction endonucleases.
  • the DNA patterns indicate the correct orientation of the inserted NS1 sequence into the pSC11-Orth vector and confirms the size of the fragments as deduced from the nucleotide sequence of clone 17-6.
  • FIGURE 14, referred to in Example 14 shows the cloning of NS1 with its putative signal sequence into the transfer vector pTKgptF3s, for recombination with vaccina virus.
  • FIGURE 15 also referred to in Example 14, shows the nucleotide sequence of the plasmid pTKtSNS1556 at the 5′ and 3′ termini.
  • the NS1 has 24 additional nucleotides corresponding to eight amino acids in its expected translation product from the polylinker region at its 5′-end.
  • An additional 26 nucleotides ie 9 amino acids are found at the 3′-end.
  • Asterisks indicate the nucleotide positions in the TBE virus genome, taken from FIGURE 3.
  • FIGURE 16 shows a southern blot analysis of NS1 vaccinia recombinants varecNS1444 and varecNS1556.
  • CV-1 cells infected with recombinant vaccinia viruses at a multiplicity of 5 pfu/cell.
  • Two days after infection total cellular DNA was purified, digested with the restriction endonuclease Hin dIII and separated on 1% agarose gel. The DNA was transferred onto a nitrocellulose filter and hybridized with the radioactively labelled plasmid pSCtSNS1444 as a probe for the detection of the inserted NS1 fragment and adjacent viral tk sequences.
  • varecNS1556-112, -124, -122 and varecNS1444-121 shows the expected upshift of the Hind III fragment towards a higher molecular weight. Only varecNS1556-222 shows a minor band corresponding to the w.t. fragment. This indicates that the plaque isloate is not homogeneous. 1556-122 etc. are different plaque isolates from the same recombination experiment after three plaque purfications. As controls and as size markers, different digests of the plasmid pSCtSNS1444 were used (slots 6 and 7).
  • FIGURE 17, referred to in Example 16 shows an autoradiograph of a denaturing SDS gel showing the recombinant viruses varecNS1444 and varecNS1556 expressing NS1 protein.
  • a protein with an expected molecular weight of about 48kD can be detected which is not found in wild type or varec1342 (expressing a different protein) infected cells.
  • the very strong protein band migrating above the 97kD marker band represents ⁇ -galactosidase (116kD) which is expressed under the control of the P11 promotor in the pSC11-Orth derived recombinants varecNS1444 and varec1342.
  • Nucleic acid in accordance with the present invention may be prepared and the sequence determined by the following general procedures:
  • viral RNA may be extracted from Western subtype TBE virus or Western subtype TBE virus infected cells.
  • a double stranded cDNA may be synthesised, for example by reverse transcriptase.
  • this cDNA may be inserted into a vector DNA such as Escherichia coli plasmid DNA to yield a recombinant plasmid.
  • Recombinant plasmids may be used to transform appropriate host cells such as E. coli strain HB101 for amplification of the plasmids or the expression of the corresponding proteins.
  • Western subtype TBE viral RNA may be obtained from purified virus.
  • Western subtype TBE virus can be grown in primary chick embryo cells, concentrated by ultracentrifugation, and purified by two cycles of sucrose density gradient centrifugation. After solubilising the proteins with SDS in the presence of proteinase K and RNAse inhibitor, eg by incubating for 1 hour at 37°C, the RNA is extracted with, for example, phenol, and precipitated with ethanol.
  • RNA complementary to the virus RNA is then synthesised in vitro by a reverse transcriptase, eg from avian myeloblastosis virus, for instance by the method of Gubler and Hofmann ( Gene 25 , 263-269, 1983).
  • a reverse transcriptase eg from avian myeloblastosis virus
  • RNAse H RNAse H under defined conditions which generates nicks in the RNA of the hybrid molecule.
  • coli DNA polymerase I can then be used efficiently to replace the RNA strand utilising the nicked RNA as primers.
  • the double-stranded RNA thus obtained is deproteinised by phenol-chloroform extraction, precipitated with ethanol and remaining RNA fragments are removed by treatment with RNAse (eg in TE buffer, 37°C, 30min).
  • dsDNA Cloning of the dsDNA is performed, eg by the use of synthetic linkers.
  • the dsDNA is treated with the Klenow fragment of E. coli DNA polymerase I under appropriate conditions (Maniatis et al , Molecular Cloning, CSH 1982) to ensure a maximum amount of clonable blunt ends, followed by phenol extraction for deproteinisation.
  • dsDNA is incubated under appropriate conditions with Bam HI linkers in the presence of DNA ligase. The reaction mixture is loaded and run on a 1% agarose gel and different size classes of cDNA are cut out of the gel and purified, eg by electroelution.
  • a plasmid DNA to be used as vector DNA eg E.
  • coli plasmid BLUESCRIPT SK- is cut with the restriction endonuclease Bam HI and dephosphorylated by the use of bacterial alkaline phosphatase. After digestion of the cDNA with Bam HI it is mixed with the Bam HI -cut vector DNA and incubated at appropriate conditions to allow for hybridisation of the complementary overhanging sequences at the ends of both DNA molecules and ligated by the use of T4-DNA ligase. The recombinant DNA molecule is used to transform a competent E. coli strain (eg E. coli XL 1-blue). Recombinants containing virus specific inserts are identified by colour selection.
  • a competent E. coli strain eg E. coli XL 1-blue
  • Plasmids are isolated by the mini-plasmid preparation method (Birnboim and Doly, Nucleic Acids Research 7 , 1195-1204, 1979) and insert sizes are analysed by restriction enzyme analyses using Bam HI and separation of the fragments obtained on 1% agarose gels.
  • the base sequence of these inserts is determined by the dideoxy chain termination method according to Sanger et al ( PNAS USA , 74 , 5463-5467, 1977). The sequence obtained is analysed for homologies with already known sequences of other flaviviruses (Rice et al, Science 229 , 726-733, 1985; Dalgarno et al, J. Mol. Biol , 187 , 309-323, 1986; Castle et al, Virology 147 227-236, 1985; Castle et al, Virology 149 , 10-26, 1986; Wengler et al, Virology 147 , 264-274, 1985; Yamshchikov and Pletnev Nucleic Acid Res .
  • Figure 2 shows the complete nucleotide sequence and Figure 3 the corresponding amino acid sequence of the NS1 region of the western subtype TBE virus genome.
  • the present invention therefore for the first time provides the nucleotide sequence of the gene coding for the NS1 protein of the Western subtype TBE virus and, as a consequence, also provides the amino acid sequence of this protein.
  • the base sequence in Figure 2 is a preferred example for a DNA which codes for polypeptides having the characteristics of the Western subtype TBE virus NS1 protein. Due to the degeneration of the genetic code, the same amino acid sequence may also be coded for by base triplets other than those shown in the Figure.
  • sequences included which are altered by mutation, transposition and degradation, which nevertheless code for an amino acid sequence still having the essential antigenic characteristics of the NS1 protein.
  • the invention does not only relate to exactly the same amino acid sequence as that shown in Figure 3, which represents only an exemplary sequence of the NS1 sequence of a natural Western subtype TBE virus isolate. It is a well-known fact that the genomes of RNA viruses are subject to higher mutation frequencies than those found with DNA viruses or cellular genes due to the high error rate of RNA polymerases and the lack of proof-reading mechanisms (Holland et al , Science 215 , 1577-1585, 1982; Reanney, Ann. Rev. Microbiol. 36 , 47-73, 1982).
  • RNA viruses can be antigenically more stable under natural ecological conditions, presumably due to functional constraints which do not allow for extensive structural changes in antigenically active proteins. Nevertheless, a certain degree of variation has to be taken into account and can be demonstrated by sequence comparison of different natural isolates.
  • the invention therefore includes all sequences which hybridise under stringent conditions, eg selecting for at least 90% nucleotide sequence homology with the sequences or parts of the sequences disclosed and which preferably code for proteins or peptides having the essential antigenic determinant characteristics of the Western subtype TBE virus structural proteins.
  • Insertion of the nucleotide sequence coding for a protein such as NS-1 into appropriate vector(s) and host cells for expression at high level is a powerful technology for the study of the structure and biological function(s) of the protein.
  • the expression system to be used is always dependent on certain molecular characteristics e.g. post-translational modification of the protein molecule of interest.
  • Expression can be performed in prokaryotic or eukaryotic cell systems.
  • glycoproteins such as NS-1 expression would better be performed in a eukaryotic host cell capable of proper glycosylation.
  • a preferred expression system consists of vaccinia virus and a primate cell growing continuously in culture. This ensures, or helps to ensure, that correct post translational modifications and high level synthesis can be achieved.
  • NS-1 is part of a polyprotein which is post-translationally processed into individual proteins by cellular and viral protcases (Mandl et al ., Virology 173 291-301 (1989)).
  • synthesis of NS-1 involves an internal signal sequence at the NH 2 -terminus. The signal directs the nascent polypeptide chan into the lumen of the endoplasmic reticulum, which is necessary for proper post-translational modifications such as glycosylation.
  • this or a heterologous signal sequence has to be included in the recombinant molecule.
  • NS-1 is part of a polyprotein it does not contain start and stop codons for translation. These have to be provided by specific recombinant DNA manipluations.
  • Hydrophobic (5′) signal and (3′) anchor sequences are included in the sequence of clone 17-6 ( Figure 3).
  • the lack of appropriate endonuclease restriction sites does not allow straightforward cloning of NS-1 with its "natural" signal sequence into insertion vectors. Therefore, a stretch of 1200 bp comprising the NS-1 signal sequence and the sequence of the mature NS-1 may be synthesised, for example, in a polymerase chain reaction (PCR). This technique also allows the introduction of optional restriction sites on both sides of the amplified DNA, as well as start and signal sequences.
  • PCR polymerase chain reaction
  • a specifically designed primer-pair for the amplification results in an NS-1 sequence product flanked by recognition sites for the restriction endonuclease Eco RI.
  • Using this methodology it is possible to exchange the authentic NS-1 signal sequence by any signal sequence naturally occuring or by a synthetic consensus signal sequence according to the proposals by v.Heinje ( NAR 14 4683-4690 (1986)).
  • All plasmids can be transposed into a parental vaccinia virus (strain WR or attenuated derivates of the same) by homologous recombination in permissive host cell e.g. primate CV-1 cells.
  • a parental vaccinia virus strain WR or attenuated derivates of the same
  • the experimental procedure to generate recombinant vaccinia viruses is common knowledge, is well known to those skilled in the art and does not need to be described (Mackett et al . JRL Press; "DNA cloning II" Ed. DM Glover 191-211, 1985).
  • the present invention also relates to the synthesis of NS-1 molecules in a bacterial host.
  • Glycoproteins expressed in bacterial cells are usually not glycosylated in the same manner as in eukaryotic cells. Nevertheless synthesis of NS-1, even in a non-glycosylated form, may be useful for different purposes.
  • derivatives of the envelope glycoprotein (gp) 160 of HIV-1 expressed in bacterial cells have significantly contributed to HIV-diagnosis and experimental vaccination.
  • an NS-1 sequence including its authentic signal sequence is synthesised with the PCR and cloned into, for example, pUC-19.
  • a substitution of the TBE signal sequence by a prokaryotic signal sequence in order to obtain efficient secretion of NS-1 molecules from the bacterial cells is possible. The latter may prevent the aggregation of NS-1 and formation of inclusion bodies that have to be dissolved with detergents or other solubilising agents.
  • Truncated molecules can be used to induce an immune response directed to specific sites of the protein. Such forms can also be valuable tools for performing "site directed serology”. Immunologically relevant epitopes within the NS-1 may become incorporated into carrier molecules as adjuvants (e.g. HB-core particles) or into an immunstimulating complex (ISCOM) (Morein et al . Immunology Today 8 (11) 333-338 (1987)).
  • carrier molecules e.g. HB-core particles
  • ISCOM immunstimulating complex
  • NS-1 molecules synthesised in prokaryotic and eukaryotic expression systems described in this application represent molecules suitable as candidate NS-1 vaccine. either alone or perhaps by combining it with the recombinant glycoprotein-E of TBE-virus (EP-A-0284791) or the already available vaccine consisting of inactivated TBE-virus.
  • the analysis of the immune response against this non-structural protein or parts thereof may be critical for understanding the pathogenicity of the TBE-virus and other members of the flavi-virus family.
  • Foreign DNA or RNA sequences can also be engineered into the genomes of live viruses thus generating recombinant viruses which can be used as a live vaccine (for review, see Mackett and Smith, J. Gen. Virol. 67 , 2067-2082, 1986).
  • genes eg derived from different viruses
  • the invention therefore includes any combinations of sequences out of the sequences disclosed with other sequences, such as genes coding for other proteins or sequences contributing to the expression of the proteins, such as promoters, enhancers, polyadenylation or splicing signals.
  • Proteins or parts of proteins to be used as vaccines or diagnostic reagents can not only be prepared by the recombinant DNA technologies described above, but the sequence information disclosed in the present invention can also be used for the chemical synthesis of oligopeptides.
  • sequence information disclosed in the present invention can also be used for the chemical synthesis of oligopeptides.
  • peptides synthesised according to DNA sequences coding for many different proteins have been prepared and used for a variety of purposes such as molecular biological and immunological studies (Lerner et al , Cell , 23 , 309-310, 1981; Lerner, Nature , 299 , 592-596, 1982) or vaccination (Shinnick et al , Ann. Rev. Microbiol.
  • nucleic acids and sequences provided by the present invention for the preparation of hybridisation probes eg for the use of determining virus RNA in ticks or blood-fluid (Meinkoth and Wahl, Anal. Biochem. 138 , 267-284, 1984; Kulski and Norval, Arch. Virol. 83 , 3-15, 1985). These can be prepared either by recombinant DNA technologies or by the chemical synthesis of oligonucleotides according to the sequence disclosed.
  • a 10% suspension of TBE virus-infected suckling mouse brain was used for the infection of primary chick embryo cell monolayers maintained in minimum essential medium (MEM) buffered with 15mM HEPES and 15mMEPPS at pH 7.6. After 40h incubation at 37°C the supernatant was clarified at 10000g for 30min at 4°C and the virus was pelleted by ultracentrifugation at 50000g for 3h at 4°C.
  • MEM minimum essential medium
  • the virus was then resuspended in an appropriate volume of TAN buffer (0.05M triethanolamine, 0.1M NaCl, pH 8.0) and subjected to rate-zonal centrifugation in a 5-20% (w/w) sucrose density gradient at 170000xg for 110min at 4°C.
  • the virus peak was located by scanning the gradient at 254nm and subjected to equilibrium density gradient centrifugation in a 20 to 50% (w/w) sucrose gradient for 18 h/4°C at 150000xg.
  • the virus peak was dialysed against TAN pH 8.0 to remove excess sucrose.
  • an aliquot of the RNA was denatured with glyoxal and run on a 1% agarose gel in order to check the yield and the quality of the preparation.
  • RNA 5 ⁇ g of ethanol precipitated RNA were resuspended in 40 ⁇ l of first strand synthesis buffer (Amersham, UK) that contained 5 ⁇ g of random oligonucleotide primers, heated to 70°C for one minute and then allowed to cool slowly to room temperature. All four deoxynucleotide triphosphates were added to final concentrations of 1mM. Furthermore, 5 units of human placental ribonuclease inhibitor and 10 ⁇ Ci of ⁇ - 32 P dCTP were added to the mixture. First strand synthesis was started by the addition of 100 units of reverse transcriptase (Amersham) and allowed to proceed for 2 hours at 42°C.
  • reaction mixture was placed on ice and the reagents for the second strand synthesis were added in this order: 93.5 ⁇ l of second strand synthesis buffer (Amersham, UK), 4 units of ribonuclease H, 23 units of E. coli DNA polymerase and water to a final volume of 250 ⁇ l.
  • Second strand synthesis was carried out by subsequent incubations at 12°C and 22°C (2 hours each) and stopped by heating the solution for 20 minutes to 70°C.
  • the double stranded cDNA was digested with 10 units of T4 DNA polymerase for 30 minutes at 37°C in order to create blunt ends. Finally the cDNA was purified by phenol and chloroform extractions and precipitated with 2 volumes of ethanol.
  • Synthetic 5′-phosphorylated Bam HI linkers (New England Biolabs) were added onto the cDNA in an overnight reaction at 12°C.
  • the reaction mixture contained in a final volume of 20 ⁇ l of ligation buffer (50mM Tris pH 7.5, 5mM MgCl 2 , 5mM DTT, 1mM ATP) approximately 1 ⁇ g of cDNA, 1 ⁇ g of linker DNA and 1 ⁇ l of T4 DNA ligase (New England Biolabs).
  • the cDNA was fractionated on a 1% agarose gel. Different size fractions were cut out of the gel and the DNA was extracted from the agarose in an analytical electroeluter (IBI) according to the manufacturer's directions. In spite of the small amount of DNA handled, which could hardly be detected by ethidium bromide staining, the extraction procedure could easily be monitored due to the radioactive label incorporated into the cDNA.
  • the size fractionation step provided a means of selectively cloning large fragments of cDNA and also served to completely separate the cDNA from unligated linker molecules.
  • the cDNA was digested with 10U of Bam HI restriction endonuclease for 1hr at 37°C. After phenol and chloroform extractions the DNA was precipitated with 2 volumes of ethanol and resuspended in a small volume of water. 20 - 30ng of the cDNA were mixed with 50ng of the phagemid BLUESCRIPT SK- (Stratagene) that had been linearized by Bam HI digestion. (The word BLUESCRIPT is a trade mark.) These two components were litigated by T4 DNA ligase in 10 ⁇ l of ligation buffer (see above) in an overnight reaction at 16°C.
  • the ligation mixture was heated to 65°C for 5min, diluted hundredfold with water and used to transform E. coli XL1 Blue cells. Competent bacteria were purchased from Stratagene and transformed with 3 ⁇ l of the diluted ligation mixture exactly following the protocol provided by the manufacturer. Bacteria were plated onto LB agar plates containing ampicillin, tetracyclin, IPTG and X-Gal.
  • Figure 1 shows a 1% agarose gel of a quick plasmid preparation of BS 17-6 both in the supercoiled circular and the Bam HI digested forms.
  • Single stranded DNA of the clone BS 17-6 was prepared by addition of the VCS helper phage (Stratagene) at a M.O.I. of 20:1 to exponentially growing cultures of 85 17-6 containing E. coli XL1 Blue bacteria. After agitating vigorously the culture at 37°C for 16 hrs ssDNA was purified from the supernatant according to standard protocolls.
  • This single-stranded DNA was sequenced in the whole region of the insert by the dideoxy method of Sanger et al ( PNAS USA 74 , 5463-5467; 1977) using the SEQUENASE enzyme (United States Biochemicals) and the reagents supplied by the enzyme-manufacturer. (The word SEQUENASE is a trade mark.) A vector specific and a set of virus-sequence specific oligonucleotides were used as primers for the sequencing reactions. The complete sequence of the insert 17-6 is shown in Figure 2.
  • Figure 3 depicts the RNA sequence and the encoded amino acid sequence derived from clone 17-6.
  • the amino terminus of NS1 is supposed to be released by a cellular signalase, the carboxy-terminus by a signalase-like enzyme.
  • a larger form of the NS1 protein that contains also the amino-terminal part of the protein NS2A was observed by Mason et al ( Virology 158 , 361-372 (1987)).
  • the carboxy-terminus of this form of the NS1 protein may be liberated by a virus-specified protease or the cellular signalase (Rice et al, Science 229 , 726-733 (1985)).
  • the amino-terminus and three possible carboxy-termini are indicated in Figure 3.
  • the carboxy-terminus liberated by a signalase-like enzyme (Chambers et al ., Virology 169 100-109 (1988)) is depicted as "COOH-Terminus 1 ⁇ ; the carboxy-terminus possibly formed by a probably virus-specified protease is indicated as “COOH-Terminus 2 ⁇ ; and the potential carboxy terminus liberated by the cellular signalase is shown as "COOH-Terminus 3".
  • the position numbers used in Figure 3 relate to the full length genome of TBE virus.
  • Figure 4 shows the amino acid sequence of protein NS1 as derived from the sequence information of clone 17-6. The possible COOH-Termini are indicated as in Figure 3. Position numbers are counted from the first amino acid of protein NS1. Figure 4 also depicts the locations of the three potential N-glycosylation sites present in the TBE virus protein NS1.
  • the nucleotide sequence coding for NS1 is subcloned from clone 17-6 into pUC19.
  • the vector pUC19S is a derivative of pUC19S containing a stop linker with a TAG stop codon in all three reading frames cloned into the Bam HI site.
  • the NS1 sequence containing a small part of NS2a at its 3′-end is excised with restriction endonuclease Cfo I and blunt ends are generated with S1-Nuclease.
  • the cloning vector pUC19S is linearized in its polylinker with Sal I and termini are filled-in with T4 DNA Polymerase ( Figure 5).
  • Ligation of vector and insert regenerates the Sal I sites and fuses NS1 in frame to the lacZ gene ( Figures 6A and 6B).
  • the NS1 nucleotide sequence is flanked by the prokaryotic transcriptional and translational stop signals contained in the vector.
  • the plasmid is designated pNS1387.
  • Example 12 Construction of a plasmid for recombination into Vaccinia Virus: the NS-1 protein under the control of the VV-p11 (L) promotor)
  • the NS-1 coding region (eg. in Example 10) is subcloned into the Sal I site of plasmid pTKgptF1s (Falkner, G.F. and B. Moss, ( J . Virol 62 ,1849-1854 (1988)).
  • the NS1 sequence is positioned in frame with the ATG translational start codon of the vector. Translational stop signals are also provided by the vector.
  • the polylinker region of the vector adds an additional 7 aminoacids at the 5'end and 10 aminoacids at the 3'end.
  • the cloning strategy and the flanking sequences of the protein are shown in Figure 8a and 8b.
  • the plasmid is designated pAPNS1338.
  • Example 13 Construction of a plasmid for recombination into Vaccinia Virus the NS-1 protein with its natural signal sequence under the control of the VV-D7.5 (E/L) promotor
  • a nucleotide sequence comprising the NS1 coding region and its signal sequence is synthesized by the Polymerase Chain Reaction using clone 17-6 as a template.
  • Two oligonucleotides with the restriction endonuclease cleavage sites Eco RI and Sal I at the 5'end and Sal I and Hpa I at the 3'end are chemically synthesized and used as primers in PCR (Figs 9A and 9B).
  • the amplified NS1 fragment is purified from an agarose gel (Fig. 10) cleaved with Sal I and cloned into the Sal I site of the vector pSC11-Orth after minor modifications.
  • the plasmid pSC11-Orth has been deposited at the D.S.M., Braunschweig, West Germany, as DSM 5734 on 15th January 1990.
  • the cloning strategy and sequences of the 5′ and 3′ termini of the new construct are shown in Figures 11 and 12.
  • An agarose gel of a restriction digest of the clone confirming the correct orientation of the insert is shown in Figure 13.
  • the plasmid is designated pSCtSNS1444.
  • Example 14 Construction of a plasmid for recombination into vaccinia virus: the NS-1 protein with its original signal sequence under the control of the VV-p11 (L) promotor
  • Plasmid pTKtSNS1556 results from subcloning of NS1 from clone pSCtSNS1444 into the vector pTKgptF3s (Falkner and Moss ( J . Virol 62, 1849-1854 (1988)).
  • the NS1 sequence is exised with Sal I and inserted into the Sal I site of pTKgptF3s.
  • the cloning strategy and nucleotide sequences of pTKtSNS1556 are shown in Figures 14 and 15.
  • All plasmids are grown under ampicillin selection of 100 ⁇ g/ml in E. coli hosts like DK1, BH101 or JM strains (JM105, JM83).
  • Recombinant viruses are generated according to standard procedures (Mackett, M., Smith, G. and Moss, B. In: DNA Cloning: A Practical Approach, pp 191-121. Edited by D.M. Glover; Oxford: IRL Press).
  • the plasmid DNA of pSCtSNS14444 and of pTKtSNS1556 are transfected into CV-1 cells infectedwith vaccinia virus wild type.
  • the pSC11-Orth-derived recombinant varecNs1444 is selected for with BuDR on 143tk-cells.
  • Th pTKgptFs derived recombinant varecNS1556 is isolated by gpt selection on CV-1 cells. All recombinants were plaque purified three times. The correct organization of the recombinants is analysed by Southern blot analysis (Fig. 16).
  • CV-1 cells are infected with the vaccinia virus recombinants varecNS1444 and varecNS1556. Two days after infection the cells are labelled with 35-S methionine for 4 hours. Proteins are separated on a 12% SDS denaturing polyacrylamide gel and identified by autoradiography. A protein band corresponding to an expected molecular weight of about 48 kD can be detected. It is missing in cells with wild type virus or non-NS1 recombinants like varec1342 (Fig. 17).

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EP90306154A 1989-06-06 1990-06-06 Proteins, vaccines and nucleic acids Expired - Lifetime EP0402116B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP89305708 1989-06-06
EP89305708 1989-06-06

Publications (2)

Publication Number Publication Date
EP0402116A1 EP0402116A1 (en) 1990-12-12
EP0402116B1 true EP0402116B1 (en) 1996-09-25

Family

ID=8202711

Family Applications (1)

Application Number Title Priority Date Filing Date
EP90306154A Expired - Lifetime EP0402116B1 (en) 1989-06-06 1990-06-06 Proteins, vaccines and nucleic acids

Country Status (12)

Country Link
EP (1) EP0402116B1 (cs)
JP (1) JPH03151878A (cs)
AT (1) ATE143373T1 (cs)
CA (1) CA2018332A1 (cs)
CZ (1) CZ277921B6 (cs)
DD (1) DD297997A5 (cs)
DE (1) DE69028658T2 (cs)
FI (1) FI902814A0 (cs)
HU (1) HUT54306A (cs)
NO (1) NO902491L (cs)
SK (1) SK277781B6 (cs)
YU (1) YU109590A (cs)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4224402A1 (de) * 1992-07-21 1994-01-27 Schering Ag Neue Pyridin-Derivate mit Leukotrien-B¶4¶-antagonistischer Wirkung
FR2794865B1 (fr) * 1999-06-09 2003-04-18 Pasteur Institut Methode de detection precoce des flavivirus et ses applications

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2074422T3 (es) * 1987-03-20 1995-09-16 Immuno Ag Moleculas de adn y arn del subtipo accidental del virus fsma, polipeptidos, que son codificados por estas moleculas, y su uso.
IL91304A0 (en) * 1988-08-20 1990-03-19 Us Health Recombinant vaccinia virus for prevention of disease caused by flavivirus

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, vol. 97, no. 23, 06 December 1982, Columbus, OH (US); F.X. HEINZ et al., p. 317, AN 195475s *
JOURNAL OF GENERAL VIROLOGY, vol. 70, 1989, SGM, GB; J.M. LEE et al., pp. 335-343 *

Also Published As

Publication number Publication date
FI902814A0 (fi) 1990-06-05
ATE143373T1 (de) 1996-10-15
DD297997A5 (de) 1992-01-30
JPH03151878A (ja) 1991-06-28
DE69028658D1 (de) 1996-10-31
EP0402116A1 (en) 1990-12-12
CA2018332A1 (en) 1990-12-06
HUT54306A (en) 1991-02-28
NO902491L (no) 1990-12-07
SK277781B6 (en) 1995-01-05
YU109590A (sh) 1992-07-20
HU903490D0 (en) 1990-10-28
DE69028658T2 (de) 1997-03-06
CS9002806A2 (en) 1991-11-12
NO902491D0 (no) 1990-06-05
CZ277921B6 (en) 1993-06-16

Similar Documents

Publication Publication Date Title
Casais et al. Reverse genetics system for the avian coronavirus infectious bronchitis virus
Zsak et al. An African swine fever virus virulence-associated gene NL-S with similarity to the herpes simplex virus ICP34. 5 gene
US5744141A (en) Flavivirus recombinant poxvirus immunological composition
US5514375A (en) Flavivirus recombinant poxvirus vaccine
JP3826055B2 (ja) 組換えアビポックスウイルスによる免疫方法
JP2002325593A (ja) キメラおよび／または増殖制限されたフラビウイルス
Vennema et al. Genomic organization and expression of the 3′ end of the canine and feline enteric coronaviruses
CA2237807C (en) Recombinant poxvirus-feline infectious peritonitis virus, compositions thereof and methods for making and using them
CA2414339C (en) Bvdv virus-like particles
Li et al. Expression of the M gene of vesicular stomatitis virus cloned in various vaccinia virus vectors
EP0614979B1 (en) Hog cholera virus vaccine and diagnostic
EP0402116B1 (en) Proteins, vaccines and nucleic acids
Gong et al. A single point mutation of Ala-25 to Asp in the 14,000-Mr envelope protein of vaccinia virus induces a size change that leads to the small plaque size phenotype of the virus
US6521236B1 (en) Vector vaccine of recombinant feline herpesvirus
CA2495294C (en) Replicons of pestiviruses that do not express c and or e1 protein and infectious viral particles containing same, that can be used in vaccines
US5439814A (en) DNA encoding infectious rubella virus
US5663065A (en) DNA encoding infectious Rubella virus
GB2624391A (en) Recombinant LSDV vectored bovine coronavirus antigen constructs
Carroll Expression analysis and immunogenicity of human immunodeficiency virus type 1 envelope glycoprotein in vaccinia virus
JPH07502173A (ja) 偽性狂犬病ウイルスワクチン
JPH06253852A (ja) Ｃｃｖワクチン
JPH06100465A (ja) フラビウイルス科に属するウイルスの組み換え生ワクチン
Wittek et al. Sequence Analysis and Expression of the

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

17P Request for examination filed

Effective date: 19910605

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: IMMUNO AKTIENGESELLSCHAFT

17Q First examination report despatched

Effective date: 19940114

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Effective date: 19960925

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 19960925

Ref country code: ES

Free format text: THE PATENT HAS BEEN ANNULLED BY A DECISION OF A NATIONAL AUTHORITY

Effective date: 19960925

Ref country code: DK

Effective date: 19960925

Ref country code: CH

Effective date: 19960925

Ref country code: BE

Effective date: 19960925

REF Corresponds to:

Ref document number: 143373

Country of ref document: AT

Date of ref document: 19961015

Kind code of ref document: T

ITF It: translation for a ep patent filed
REF Corresponds to:

Ref document number: 69028658

Country of ref document: DE

Date of ref document: 19961031

ET Fr: translation filed
REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19970630

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
REG Reference to a national code

Ref country code: GB

Ref legal event code: IF02

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20030521

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20030522

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20030528

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20030619

Year of fee payment: 14

Ref country code: FR

Payment date: 20030619

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20030630

Year of fee payment: 14

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20040606

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20040606

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20040607

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20050101

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20050101

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20040606

EUG Se: european patent has lapsed
EUG Se: european patent has lapsed
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20050228

NLV4 Nl: lapsed or anulled due to non-payment of the annual fee

Effective date: 20050101

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED.

Effective date: 20050606